Protecting Free Vaccines Act

HR5448, titled the 'Protecting Free Vaccines Act,' was introduced in the House on September 18, 2025, and subsequently referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce. This indicates the bill is in its initial legislative phase. The bill aims to require Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and private health insurers to cover, without cost-sharing, vaccines recommended by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) as of October 25, 2024, until January 1, 2030. The bill does not authorize or appropriate a specific dollar amount; instead, it mandates coverage requirements. The financial mechanism involves shifting the cost of ACIP-recommended vaccines from individuals to government programs (Medicare, Medicaid, CHIP) and private health insurers. This guarantees a market for these vaccines, effectively increasing the total addressable market for vaccine manufacturers by removing cost as a barrier for consumers. The bill's sponsor, Rep. Pallone, is a senior Democrat, and the presence of 72 cosponsors suggests a degree of legislative support, though it remains in committee. Structural winners, should this bill pass, are vaccine manufacturers such as Pfizer Inc. ($PFE), Moderna, Inc. ($MRNA), GSK plc ($GSK), Novartis AG ($NVS), and Johnson & Johnson ($JNJ), as the guaranteed no-cost coverage would drive increased demand and sustained revenue streams for their vaccine products. Conversely, health insurers like UnitedHealth Group Incorporated ($UNH), Elevance Health, Inc. ($ELV), and CVS Health Corporation ($CVS) (through its Aetna segment) would face increased cost burdens due to the mandated no-cost coverage. The bill's text explicitly states that group health plans and health insurance issuers "shall provide coverage for and shall not impose any cost sharing requirements for immunizations." Looking at recent market data, vaccine manufacturers show mixed performance over the last 30 days: $PFE is up +4.58%, $GSK is up +1.99%, and $JNJ is up +0.56%, while $MRNA is down -9.4% and $NVS is down -5.07%. Health insurers show varied trends: $UNH is down -2.57%, $ELV is up +5.63%, and $CVS is down -6.88% over the last 30 days. These movements reflect broader market dynamics and are not directly attributable to this early-stage bill. The bill's current status is "Referred to committee," meaning it has several legislative steps remaining, including committee consideration, potential floor votes in both chambers, and presidential assent. There is a related Senate bill, S2857, also titled 'Protecting Free Vaccines Act of 2025,' which is a companion bill. This indicates a coordinated effort in both chambers, which can increase the probability of eventual passage. However, the bill is still in the early stages of the legislative process, with no committee reports or amendments yet. The requirement ends on January 1, 2030, providing a defined period for the mandated coverage.